Insulin Therapy in Small Animals, Part 1: General Principles.

Area of Science:

• Veterinary Pharmacology
• Endocrinology
• Diabetes Mellitus Management

Background:

• Understanding insulin pharmacology is crucial for effective diabetes mellitus treatment in animals.
• Various insulin formulations exist, but not all are suitable for consistent basal insulin therapy.
• The ideal basal insulin should provide a steady effect throughout the day.

Purpose of the Study:

• To evaluate different insulin formulations for their suitability as basal insulins in veterinary medicine.
• To identify insulin products that provide a consistent, predictable pharmacokinetic profile in diabetic animals.
• To compare the efficacy and safety of various insulin types for long-term diabetes management.

Main Methods:

• Review of pharmacokinetic and pharmacodynamic data for commonly used insulin suspensions and analogues.
• Analysis of insulin action profiles, focusing on duration and consistency of effect.
• Comparison of insulin formulations based on their suitability for twice-daily or continuous basal insulin delivery in dogs and cats.

Main Results:

• Intermediate-acting insulins (NPH, lente, PZI, glargine U100, detemir) are typically administered twice daily and do not offer consistent hourly action.
• In dogs, only insulin glargine U300 and insulin degludec demonstrate a pharmacokinetic profile suitable for basal insulin therapy, providing relatively constant action.
• In cats, insulin glargine U300 is the closest available option to meeting the standard for consistent basal insulin action.

Conclusions:

• The selection of an appropriate insulin formulation is critical for successful diabetes management in animals.
• Insulin glargine U300 and insulin degludec represent advancements in basal insulin therapy for dogs due to their consistent action.
• Further research or formulation development may be needed to achieve ideal basal insulin characteristics in cats.